Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1419882

Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: A case report

Provisionally accepted
Suoshi Jing Suoshi Jing 1*Weiping Li Weiping Li 1Bo Zhao Bo Zhao 2Wei Jiang Wei Jiang 3Bin Zhang Bin Zhang 2
  • 1 First Hospital of Lanzhou University, Lanzhou, Gansu Province, China
  • 2 People's Liberation Army Joint Logistics Support Force 940th Hospital, Lanzhou, Gansu Province, China
  • 3 Air Force HealthCare Center for Special Services Hangzhou, Hangzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Background: For patients with metastatic upper tract urothelial carcinoma (UTUC), the preferred first-line treatment is platinum-based chemotherapy. Immunotherapy can be considered a subsequent treatment if the chemotherapy is ineffective or the disease progresses. However, how should treatment be administered if immunotherapy is useless and the patient cannot take chemotherapy? Especially in patients who have metastasized after radical nephroureterectomy (RNU).Case presentation: A 68-year-old woman was admitted to the hospital due to left flank pain for two weeks and was diagnosed with metastatic UTUC after RNU. The patient underwent systemic chemotherapy with gemcitabine and cisplatin (GC), as well as reduced-dose GC, but developed myelosuppression. Immunotherapy was ineffective, so Disitamab vedotin (RC48) was chosen.Results: Disitamab vedotin (RC48) monotherapy was administered for 13 cycles, during which thyroid function remained normal, the patient responded well to the treatment, and the disease was controlled well. In the subsequent two years of follow-up, there was no disease recurrence.The long-term treatment regimen with RC48 is feasible for metastatic UTUC after RNU, and RC48 monotherapy is suitable as first-line therapy for selected patients.

    Keywords: Immunotherapy, Disitamab Vedotin (RC48), metastasis, Upper tract urothelial carcinoma, GC

    Received: 19 Apr 2024; Accepted: 26 Aug 2024.

    Copyright: © 2024 Jing, Li, Zhao, Jiang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Suoshi Jing, First Hospital of Lanzhou University, Lanzhou, Gansu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.